



ISSN: 2231-3656

Print: 2231-3648

# International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR | Vol.12 | Issue 4 | Oct - Dec -2023

[www.ijpir.com](http://www.ijpir.com)

DOI : <https://doi.org/10.61096/ijpir.v12.iss4.2023.280-287>

## Research

### Formulation and development of cefidinir sustained release tablets using various retarding polymers

Syed Asadulla Bakhtiary<sup>1</sup>, Srikant Pallothu Chowdary<sup>2</sup>, Syam Prasad Borra<sup>3</sup>, Mohammed Ibrahim<sup>4</sup>

<sup>1</sup>Professor & HOD, Department of Pharmacology, Prathap Narendra Reddy College of Pharmacy, Peddashapur, Shamshad, Telangana-509325, India

<sup>2</sup>Professor, Department of Pharmaceutics, Prathap Narendra Reddy College of Pharmacy, Peddashapur, Shamshad, Telangana-50932, India

<sup>3</sup> Assistant General Manager, Hetero Labs Limited, Gandhinagar, Hyderabad, Telangana- 500037, India

<sup>4</sup>Professor & Principal, Department of Pharmaceutical Chemistry & Analysis, Prathap Narendra Reddy College of Pharmacy, Peddashapur, Shamshad, Telangana-50932, India

\*Author for Correspondence: Syed Asadulla Bakhtiary

Email: dr.asadpnrcp@gmail.com

	<b>Abstract</b>
Published on: 27 Nov 2023	The tablets of Cefidinir with sustained-release formulations primarily based on tamarind gum, carnauba wax substance, and fenugreek have been developed. Hardness, weight variation, fragility, and remedy content material have all been measured for every capsule. Concentrates used in the preliminary formulation, such as the resting point, data. The therapy grew to be given in vitro for 12 hours in a phosphate cradle with a pH of 6.8. The artificial pill has enough cutoff standards for each single actual individual. The Carnuba Wax (F6) tablet has a greater supported drug discharge (99.72%) than the framework pill. polymer- enhanced lattice pills proven that polymer enlargement impeded the shipping of medicinal drugs.
Published by: DrSriram Publications	
2023   All rights reserved.  <a href="#">Creative Commons</a> <a href="#">Attribution 4.0 International License</a> .	<b>Keywords:</b> Fenugreek, Cefidinir, Tamarind Gum, Carnuba Wax, sustained release tablets

## INTRODUCTION

For a long time, the most complete and broadly utilised approach of managed distribution of prescription by means of numerous medicinal has been implied to be the oral remedy movement. Reasons for the oral route's recognition might also encompass its convenience large doses of the drug can also be taken at once. No be counted the approach of transport (fast, supported, or regulated discharge) and the format of measuring systems, the natural aspects must be developed. (both sturdy scattering or fluid). To effectively assemble an oral medication dosage form, it is critical to acquire a requisite definition configuration.

The growing rate and challenge of advertising new additives, as nicely as the increasing reputation of

the therapeutic advantages of managed drug transport, have sparked an expanded quantity of activity in the introduction in latest years. Since supported discharge science is nevertheless tremendously novel, many discoveries have resulted from research. Many medicines are designed to keep a therapeutically nice and secure blood. Degree over an prolonged size of time<sup>(1-3)</sup>. The framework adequate measures is a main issue in attaining this goal. Names for drug shipping structures that are designed to produce a delayed therapeutic impact by way of persistently turning in cure over a lengthy duration of time after preliminary administration encompass "managed release," "extended action," "organized conveyance," and "stockroom estimations" form. The few hours of impact time after taking an oral supported furnished dosage shape relies upon on the data season at domestic in the GIT.

## MATERIALS AND METHODS

The materials used in this current research work are procured from reliable sources of Cefdinir, SURA LABS, FDC Limited, TamarindGum, Carnubawax, Fenugreek and MicroCrystallineCellulose are procured from Nihartraders pvt Ltd. All other reagents used in this research work are procured from most reliable vendors.

## METHODOLOGY

### Analytical method development

#### Determination of Calibration Curve

10mg of pure drug was dissolved in 10ml methanol (primary stock solution - 1000Lg/ml). From this primary stock solution 1ml was pipette out into 10ml volume tricflaskai1dmadeitupto 10ml with the media (Secondary stock solution-100µg/ml)<sup>(4-9)</sup>. From secondary stock solution required concentrations were prepared (shown in Table 8.1 and 8.2) and those concentrations absorbance were found out at required wavelength.

#### Preformulation parameters

The quality of tablet, once formulated is generally dictated by the quality of physicochemical properties of blends. There are many formulations and process variables involved in mixing and all these can affect the characteristics of blends produced. The various characteristics of blends tested as per Pharmacopoeia.

#### Formulation development of Tablets

All the formulations were prepared by direct compression. The compositions of different formulations are given in Table 1. The tablets were prepared as per the procedure given below and aim is to prolong the release of Cefdinir<sup>(10-16)</sup>. Total weight of the tablet was considered as 200mg.

**Table1: Formulation composition for tablets**

Ingredients	F1	F2	F3	F4	FS	F6	F7	FS	F9
Cefdinir	100	100	100	100	100	100	100	100	100
TamarindGum	10	20	30	-	-	-	-	-	-
Camubawax	-	-	-	10	20	30	-	-	-
Fenugreek	-	-	-	-	-	-	10	20	30
MicroCrystalline Cellulose	30	20	10	30	20	10	30	20	10
Talc	5	5	5	5	5	5	5	5	5
Magnesium stearate	55	55	55	55	55	55	55	55	55
Totalweight	200	200	200	200	200	200	200	200	200

All the quantities were in mg

#### Evaluation of post compression parameters for prepared Tablets

The designed Formulation tablets were studied for their physicochemical properties like weight variation, hardness, thickness, friability and mug content.

#### Weight variation test

To study the weight variation, twenty tablets were taken and their weight was determined individually and collectively on a digital weighing balance. The average weight of one tablet was determined from the collective weight. The weight variation test would be a satisfactory method of determining the mug content uniformity. Not more than two of the individual weights deviate from the average weight by more than the percentage shown in the following table and none deviate by more than twice the percentage. The mean and

deviation were determined<sup>17</sup>. The percent deviation was calculated using the following formula.

$$\% \text{ Deviation} = (\text{Individual weight} - \text{Average weight} / \text{Average weight}) \times 100$$

## RESULTS & DISCUSSION

The present study was aimed to developing sustained release tablets of Cefidinir using various polymers. All the formulations were evaluated for physicochemical properties and *in-vitro* drug release studies.

### Analytical Method

Graphs of Cefidinir were taken in 0.1N HCl and in pH 6.8 phosphate buffer at 286 respectively. As mentioned in the figure 1&2.




Fig 1: Standard curve of Cefidinir in 0.1N HCl




Fig 2: Standard curve of Cefidinir in pH 6.8 Phosphate buffer

Tablet powder blend was subjected to various pre-formulation parameters. The angle of repose values indicates that the powder blend has good flow properties. The bulk density of all the formulations was found to be in the range of  $0.46\pm 0.002$  to  $0.61\pm 0.004$  (gm/cm<sup>3</sup>) showing that the powder has good flow properties<sup>(18-23)</sup>. The tapped density of all the formulations was found to be in the range of  $0.52\pm 0.002$  to  $0.72\pm 0.005$  showing the powder has good flow properties. The compressibility index of all the formulations was found to be below 9.52-15.28 which show that the powder has good flow properties.

#### Quality Control Parameters For tablets

Tablet quality control tests such as weight variation, hardness, and friability, thickness, and drug release studies in different media were performed on the compression coated tablet.

#### Weight variation test

Tablets of each batch were subjected to weight variation test, difference in weight and percent deviation was calculated for each tablet and was shown in the Table. The average weight of the tablet is approximately in range of 195.36 to 200.05 mg, so the permissible limits  $\pm 7.5\%$  ( $>200$  mg). The results of the test showed that, the tablet weights were within the pharmacopoeial limit.

#### Hardness test

Hardness of the three tablets of each batch was checked by using Pfizer hardness tester. The results showed that the hardness of the tablets is in range of 4.2 to 4.9 kg/cm<sup>2</sup>, which was within IP limits.

#### Thickness

Thickness of three tablets of each batch was checked by using Micrometer and data shown in Table-8.4. The result showed that thickness of the tablet is ranging from 2.18 to 2.34 mm.

#### Friability

Tablets of each batch were evaluated for percentage friability (24-27). The average friability of all the simulations was less than 1% as per official requirement of IP indicating a good mechanical resistance of tablets.

#### In vitro Drug Release Studies




Fig 3: Dissolution profile of Cefidinir (F1, F2, F3 formulations)




Fig 4: Dissolution profile of Cefidinir (F4, F5, F6 formulations)






Fig 5: Dissolution profile of Cefidinir (F7, F8, F9 formulations)




**Fig 6: Zero order release kinetics graph**

From the above graphs it was evident that the formulation F6 was followed Zero order release kinetics mechanism as represented in the figure 6&7.

#### Drug -Excipient compatibility studies Fourier Transform-Infrared Spectroscopy



**Fig 7: FTIR Spectrum of Cefidinir pure drug.**



**Fig 8: FT-IR Spectrum of Optimized Formulation**

From the FTIR data it was evident that the drug and excipients doses no have any interactions as shown in the figure 8. Hence, they were compatible.

## CONCLUSION

Cefidinir sustained release matrix tablets were successfully prepared by using various polymers to retard the release and achieve the retard dissolution profile. Drug & polymer were found to become compatible as indicated by FTIR studies. From the observation it was concluded that polymers used in different concentrations differ in their ability to sustain the drug release. Further it was concluded that polymers Carnuba Wax showed better sustained release property than other polymers in the Formulation of sustained release matrix tablets. Release rate of drug from the matrix was significantly influenced by proportion of swelling of Carnuba Wax. It may be excluded from the present study that slow & controlled release of cefidinir over a period of 12 hours was obtained from formulation F6 using Carnuba Wax. The drug release kinetics revealed Zero order release kinetics pattern. Formulation and evaluation of sustained release matrix tablets of Cefidinir was found to be beneficial.

## ACKNOWLEDGEMENT

The Authors wish to express their sincere gratitude to Prathap Narendra Reddy College of Pharmacy, Peddaphur, Shamshad, Telangana, INDIA for providing necessary facilities to carry out this research work & SURAS LAB, Hyderabad, Telangana, INDIA for providing samples for the research work.

## CONFLICT OF INTEREST

We declare that we have no conflict of interest.

## REFERENCES

1. Agarwal P, Akhtar S. A comprehensive review on sustained release matrix tablets: a promising dosage form. *Univers J Pharm Res.* 2019;3(6):49-54.
2. Karvekar M, Khan AB. A brief review on sustained release matrix type drug delivery system. *J Pharm Res.* 2017;16(3):282-9. doi: 10.18579/jperkc/2017/16/3/118769.
3. Manish J, Abhay K. Sustained release matrix type drug delivery system: a review. *J Drug Deliv Ther.* 2012;2(6):142-8.
4. Lokhande SS, Phalke NN, Badadare SS. A review on sustained release technology. *World J Pharm Med Res.* 2019;5(11):60-5.

5. SivaramuKambampati JN, Kumar S, Sriram CH. A review on sustained release drug delivery system. *Int J Res Pharm Nano Sci.* 2013;2(4):441-7.
6. Sunil K, Tejasavi M, Suxam ST, Sonica P, Sohit M, Neeraj B. Sustained release matrix tablet: a review. *World J Pharm Pharm Sci.* 2018;7(10):827-39.
7. Mali RR, Goel V, Gupta S. Novel study in sustained release drug delivery system: a review. *Int J Pharm Med Res.* 2015;3(2):204-15.
8. Pundir S, Badola A, Sharma D. Sustained release matrix technology and recent advance in matrix drug delivery system: a review. *Int J Drug Res Technol.* 2013;3(1):12-20.
9. Diwedi R, Alexandar S, Chandrasekar MJN. Preparation and in vitro Evaluation of sustained release tablet formulations of metformin HCl. *Asian J Pharm Clin Res.* 2012;5(1):45-8.
10. Patel KK, Patel MS, Bhatt NM, Patel LD, Pathak NL, Patel KJ. An overview: extended release matrix technology. *Int J Pharm Chem Sci.* 2012;1(2):828.
11. Kumar S, Kant S, Prashar B. A review on sustained release drug delivery system. *Int J Inst Pharm Life Sci.* 2012;2(3):356-76.
12. Karna S, Chaturvedi S, Agrawal V, Alim M. Formulation approaches for sustained release dosage forms: a review. *Asian J Pharm Clin Res.* 2015;8(5):46-53.
13. Diwedi RO, Alexandar A, Chandrasekar MJ. Preparation and in vitro evaluation of sustained release tablet formulations of metformin HCl. *Asian J Pharm Clin Res.* 2012;5(1):45-8.
14. Patnaik AN, Nagarjuna T, Thulasiramaraju TV. Sustained release drug delivery system: a modern formulation approach. *Int J Res Pharm Nano Sci.* 2013;2(5):586-601.
15. Dixit Navin S, Bhanu DM, Sagar PS. Sustained release drug delivery system. *Indian J Res Pharm Biotechnol.* 2013;1(3):305.
16. Chauhan MJ, Patel SA. A concise review on sustained drug delivery system and its opportunities. *Am J Pharm Tech Res.* 2012;2(2):227-38.
17. Kar RK, Mohapatra S, Barik BB. Design and characterization of controlled release matrix tablets of zidovudine. *Asian J Pharm Clin Res.* 2009;2:54-6.
18. Dusane AR, Gaikwad PD, Bankar VH, Pawar SP. A review on: sustained released technology. *IJRAP.* 2011;2(6):1701-8.
19. Sampath Kumar KP, Debjit B, Shweta S, Shravan P, Dutta AS. Sustained release drug delivery system potential. *J Pharm Innov.* 2012;1(2):46-56.
20. Prathiba V, Bharath A. Formulation and evaluation of sustained release matrix tablets of lamivudine, *Pharma Buzz.* 2008;3(5):24-7.
21. Kamboj S, Saroha K, Goel M, Madhu C. Sustained release drug delivery system: an overview. *J Pharm.* 2013;1:169-81.
22. Pogula M, Nazeer S. Extended release formulation. *Int J Pharm Technol.* 2010;2:625-84.
23. Misa R, Waghmare A, Aqueel S. Matrix tablet: a promising technique for controlled drug delivery. *Indo Am J Pharm Res.* 2013;3:3791-805.
24. Patel H, Panchal DR, Patel U, Brahmhbhatt T, Suthar M. Matrix type drug delivery system: a review. *J Pharm Sci Bioscientific Res.* 2011;1(3):143-51.
25. Shoaib MH, Tazeen J, Merchant HA, Yousuf RI. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. *Pak J Pharm Sci.* 2006;19(2):119-24. PMID 16751122.
26. Miyan SS, Ramesh R, Ahamed VA. Formulation and evaluation of cefpodoxime proxetil matrix tablets by using different polymers. *Res J Pharm Technol.* 2011;4(7):1060-8.
27. Palparthi D, Kumar Reddy KN. Formulation and evaluation of cefpodoxime proxetil sustained release matrix tablets. *Indian J Res Pharm Biotechnol.* 2013;1(5):758-60.